Calth켈스
402420 · KONEX · ₩402420 · 켈스
- Market cap
- ₩3.2B
- Enterprise value
- —
- P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- ROE
- —
- Net margin
- —
Financial statements not available yet. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−57.0% from the high
₩810Today: ₩1,375 – ₩1,375₩3,200
Returns
- 1W−8.3%
- 1M−19.1%
- 3M−14.0%
- 6M+25.0%
- YTD−37.5%
- 1Y−8.3%
- Volume today
- —
- Traded today
- —
- Listed shares
- 2,348,763
- EPS (12 months)
- —
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
−7.1% on Oct 27, 2026.
We found no news, filing or broker report explaining it yet. Moves without news happen; it may come later.
Possible reasons, not certainties. Not financial advice.
Signals
Quiet- BuzzQuietBuzz 27 of 100 (50 is a normal day for this stock).
- MomentumWeak-23.6% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Calth stock overview
Calth (켈스, KRX: 402420) is listed on KONEX, in the Medical & precision devices sector. , Ltd. Its shares closed at ₩1,375 on Oct 27, 2026, down 7.09% on the day, giving it a market value of ₩3.2B.
Key facts
- Market cap
- ₩3.2B
- Sector
- Medical & precision devices
- Latest price change
- −7.09%
- As of
- Oct 27, 2026
- Main business
- , Ltd.
Quick answers about Calth
- What does Calth do?
- , Ltd. develops and manufactures point-of-care in vitro diagnostic devices and reagents, holding manufacturing approvals for 42 such products, including three reagents for high-risk viral infectious diseases. The company is also developing saliva-based diagnostic systems, rapid tests, molecular diagnostics and AI-based analysis platforms, and is researching blood exosome markers for acute ischemic stroke.
- What is the market cap of Calth?
- The market capitalisation of Calth was ₩3.2B at the close on Oct 27, 2026.
- Who are the largest shareholders of Calth?
- According to the latest official filings, the largest reported holders are Lee Dong-ho (33.32%, as of Aug 11, 2025); Korea Investment Partners (21.49%, as of Aug 8, 2025).
- When is the next earnings report from Calth?
- Korean companies rarely announce results dates in advance. Based on when Calth filed the same report in past years, its next annual results is expected between Mar 18, 2027 and Mar 21, 2027.
Company profile
Kels Co., Ltd. develops and manufactures point-of-care in vitro diagnostic devices and reagents, holding manufacturing approvals for 42 such products, including three reagents for high-risk viral infectious diseases. The company is also developing saliva-based diagnostic systems, rapid tests, molecular diagnostics and AI-based analysis platforms, and is researching blood exosome markers for acute ischemic stroke.
Written by AI from the company's latest annual report.
- Korean name
- 켈스
- Themes
- Medical devices
- CEO
- 이동호
- Founded
- Mar 2018
- Listed
- Nov 2021
- Listed shares
- 2,348,763
- Fiscal year ends
- Month 12
- Website
- www.thecalth.com/
Similar companies
- TSE131290 · ₩2.9T₩260,000+7.88%
- Kctech281820 · ₩1.8T₩91,900+6.37%
- Classys214150 · ₩1.7T₩26,500−2.57%
- Park Systems140860 · ₩1.6T₩225,500+1.12%
- Curiox Biosystems445680 · ₩1.1T₩62,300+6.13%
- DI003160 · ₩1.1T₩37,800+4.71%
- Seers458870 · ₩1T₩26,300−5.57%
- LivsMed491000 · ₩937B₩37,100+1.50%
Recent filings
See all- Investor relations (IR) eventJun 18, 2026
- Change of Head Office LocationApr 1, 2026
- Annual general meeting resultsMar 26, 2026
- Audit report submittedMar 18, 2026
- Annual report (Dec 2025)Mar 18, 2026
Titles in Korean until English translations are added.
Also known as: Calth / 켈스 / 402420 / KRX:402420
Source: KRX statistical information